New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
The spread of cardiovascular diseases has the nature of an epidemic, which is enhanced by lipid profile disorders, manifested by hypercholesterolemia. Numerous conventional pharmacological tools for lowering cholesterol associated with low density lipoproteins do not make it possible to achieve targ...
Saved in:
Main Authors: | S. K. Zyryanov, O. I. Butranova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2022-12-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/5271 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01) -
PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
by: article Editorial
Published: (2023-12-01) -
PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023-09-01) -
Assessment of the global and national market for lipid modifying agents: retrospective and innovation
by: A. V. Lokhmacheva, et al.
Published: (2023-08-01) -
Comparative effectiveness of different methods of prescribing rosuvastatin and ezetimibe in combination with PCSK9 inhibitors
by: A. A. Kuznetsov, et al.
Published: (2024-06-01)